ReviewInternational journal of environmental research and public health2021
COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping.
Review in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Diabetes mellitus and other underlying conditions in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis: a systematic review and meta-analysis.The Journal of laryngology and otology · 2022Pooled it
- Increase in Healthcare-Associated Infections: Is COVID-19 Responsible? A Narrative Review.Microorganisms · 2026Review
- Clinical profile and outcome of COVID-19 associated mucormycosis in Shiraz, South Iran: a longitudinal study.Iranian journal of microbiology · 2026Article
- Acute Invasive Fungal Rhino-Orbital Sinusitis: Current Concepts and Controversies.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Craniofacial Involvement of Mucormycosis: A Single-Center Experience of 57 Cases From Shiraz, Iran.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- Article
- Post-COVID pulmonary fungal infections: An unanticipated predicament or a ticking time bomb? Clinico-microbiological profile of cases encountered during the second wave of COVID-19 pandemic at a teaching hospital in the Himalayas with a brief literature review.Journal of family medicine and primary care · 2023Article
- Invasive Fungal Infections Associated with COVID-19.Journal of fungi (Basel, Switzerland) · 2023Review
- Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.The Lancet. Infectious diseases · 2022Review
- COVID-19-associated mucormycosis involving the maxilla.Clinical case reports · 2022Article
- COVID-19 associated mucormycosis in Assiut University Hospitals: a multidisciplinary dilemma.Scientific reports · 2022Article
- Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach.Journal of infection and public health · 2022Review
- Mucormycosis: A potential head and neck problem in COVID-19 patients.Laryngoscope investigative otolaryngology · 2022Article
- COVID-19-Associated Fungal Infections: An Urgent Need for Alternative Therapeutic Approach?Frontiers in microbiology · 2022Review
- COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis.3 Biotech · 2022Review
- Rhino-Orbital Mucormycosis After COVID-19 Recovery: A Case Report.International medical case reports journal · 2022Article
- Article
- Dental and Oral Manifestations of COVID-19 Related Mucormycosis: Diagnoses, Management Strategies and Outcomes.Journal of fungi (Basel, Switzerland) · 2021Review
- Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis.Journal of fungi (Basel, Switzerland) · 2021Article
- COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors.Journal of fungi (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Mucormycosis, a serious and rare fungal infection, has recently been reported in COVID-19 patients worldwide. This study aims to map all the emerging evidence on the COVID-19-associated mucormycosis (CAM) with a special focus on clinical presentation, treatment modalities, and patient outcomes. An extensive literature search was performed in MEDLINE (Ovid), Embase (Ovid), Cochrane COVID-19 Study Register, and WHO COVID-19 database till 9 June 2021. The primary outcome was to summarize the clinical presentation, treatment modalities, and patient outcomes of CAM. Data were summarized using descriptive statistics and presented in tabular form. This evidence mapping was based on a total of 167 CAM patients with a mean age of 51 ± 14.62 years, and 56.28% of them were male. Diabetes mellitus (73.65% (n = 123)), hypertension (22.75% (n = 38)), and renal failure (10.77% (n = 18)) were the most common co-morbidities among CAM patients. The most common symptoms observed in CAM patients were facial pain, ptosis, proptosis, visual acuity, and vision loss. Survival was higher in patients who underwent both medical and surgical management (64.96%). Overall mortality among CAM patients was found to be 38.32%. In conclusion, this study found a high incidence of CAM with a high mortality rate. Optimal glycemic control and early identification of mucormycosis should be the priority to reduce the morbidity and mortality related to CAM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.